Mineralys Therapeutics Announces $120 Million Private Placement Financing

RADNOR, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (“CKD”) and other diseases driven by abnormally elevated aldosterone, today announced that it has entered into a securities purchase agreement with institutional accredited investors to sell securities in a private placement financing (the “PIPE”) for gross proceeds of approximately $120 million, before deducting estimated fees and expenses.

Read More
Matt Paulmineralys
CIVC Partners Announces Acquisition of Datavail

January 16, 2024 – Chicago, IL–CIVC Partners, LP (“CIVC”), a Chicago-based middle market private equity firm focused on investments in the business services sector, is pleased to announce that it has acquired Datavail Corp. (“Datavail” or the “Company”) from a group of growth inverstors led by Catalyst Investors, a New York-based growth equity firm focused on investing in seed-stage, early-stage and later-stage technology and software companies.

Read More
Matt Pauldatavail
Celebrating 10 Years of Boulder Heart and the Anderson Medical Center

Bob Anderson, hailing from Brainerd, Minnesota, and Sydney Anderson, a proud native of Oklahoma City, Oklahoma, forged their life together in Boulder, Colorado, where they exchanged vows in 1976. Their journey has not only been marked by Bob’s remarkable success as a serial entrepreneur in the medical device industry but also by their commitment to philanthropy, benefiting Boulder Community Health (BCH) and numerous other local organizations.

Read More
Matt Paul
Spectrum Effect Announces Boulder Ventures Investment And Welcomes Kishen Mangat To The Board Of Directors

December 5, 2023 – Kirkland, WA – Spectrum Effect® announced today the Boulder Ventures (BV) investment into Spectrum Effect and the appointment of Kishen Mangat to its Board of Directors.

Kishen Mangat is General Partner at Boulder Ventures (BV), where he leads the firm’s enterprise 5G investment strategy. Kishen previously served as the Cisco Systems VP/GM for Mobility and co-founded multiple startups, including BroadHop, Inc.

Read More
Matt Paulspectrum effect
Colorado’s leading avalanche educator took itself to task to see what is — and isn’t — working

Billy Rankin remembers a time not long ago when someone asked his 20-person guide team at Irwin Lodge in Crested Butte how many friends they’d had die in avalanches. 

Nearly everyone raised a hand for one friend, most kept it raised for two and Rankin left his hand up as the number soared to 10. Part of that was odds: Rankin has been a ski guide and avalanche course instructor for decades and lives in Crested Butte, which he said “has a pretty high tolerance for risk.” But it also shows how crushing the consequences of shaky decision-making in the backcountry can be, which is why Rankin encourages his students to study every active avalanche accident report published by the Colorado Avalanche Information Center in a given winter, looking for “the skull and crossbones, the red flags” that are always so much easier to see in retrospect than they are in the mountains.

Read More
Matt Paul
Merc Mercure and the History of Ball Aerospace

CU Boulder and Ball Aerospace have been collaborating for decades to solve mysteries of the universe. That partnership was also the university’s first commercial spin-off and it greased the gears of an entrepreneurial engine that continues to power innovation within the university and far beyond. 

Read More
Matt Paul
Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension

RADNOR, Pa., Sept. 10, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease and other diseases driven by abnormally elevated aldosterone, today announced that full results from the Target-HTN Phase 2 trial of lorundrostat, a highly selective aldosterone synthase inhibitor, in individuals with uncontrolled hypertension (uHTN) and treatment-resistant hypertension (rHTN) were published in the Journal of the American Medical Association (JAMA)

Read More
Matt Paulmineralys
PlayMetrics Partners With Blue Star Innovation Partners to Propel Growth

MORRISVILLE, N.C., August 23, 2023 (Newswire.com) - PlayMetrics, a leading provider of operations management software for youth sports organizations, today announced a partnership with Blue Star Innovation Partners ("BSIP"). The growth-focused investment firm, founded by serial entrepreneur Rob Wechsler and backed by Dallas Cowboys owner Jerry Jones, will take a significant ownership position in PlayMetrics. 

Read More
Matt Paulplaymetrics
Joe Lefkoff 1935-2023

This week we said goodbye to our favorite Southern Jew in the Mountain West and most subtly voracious eater of life, Joe Lefkoff. Joe loved people and things so fiercely and yet so quietly: he loved a fluffy matzah ball, Moe’s BBQ, and spending hours moving between the hot tub and the swimming pool reading and sunning. He loved John Le Carre, Stephen Sondheim, Scrabble, and a well-crafted dirty joke. He loved grilling the perfect steak, going to New York and London every year to see the new theater, and chasing a royal straight flush on poker nights with his favorite guys.

Read More
Matt Paul